Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
1. Barzolvolimab met its primary endpoint but showed no clinical improvements in EoE. 2. The study confirmed mast cells are not the primary drivers in EoE symptoms. 3. Celldex will not pursue further development of barzolvolimab for EoE. 4. Favorable safety profile of barzolvolimab was maintained during the study. 5. Celldex will explore barzolvolimab in other gastrointestinal indications.